Equities research analysts expect Acorda Therapeutics Inc (NASDAQ:ACOR) to announce sales of $125.73 million for the current quarter, according to Zacks Investment Research. Six analysts have made estimates for Acorda Therapeutics’ earnings. The highest sales estimate is $148.60 million and the lowest is $116.26 million. Acorda Therapeutics posted sales of $119.39 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 5.3%. The business is expected to report its next quarterly earnings report on Thursday, April 26th.
On average, analysts expect that Acorda Therapeutics will report full-year sales of $125.73 million for the current fiscal year, with estimates ranging from $364.60 million to $383.02 million. For the next fiscal year, analysts anticipate that the company will post sales of $153.66 million per share, with estimates ranging from $85.30 million to $261.61 million. Zacks’ sales calculations are a mean average based on a survey of research firms that follow Acorda Therapeutics.
Acorda Therapeutics (NASDAQ:ACOR) last released its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported $0.61 earnings per share for the quarter, missing the consensus estimate of $0.88 by ($0.27). Acorda Therapeutics had a negative return on equity of 4.88% and a negative net margin of 37.97%. The firm had revenue of $188.40 million for the quarter, compared to analysts’ expectations of $171.70 million. During the same quarter last year, the firm posted $0.05 earnings per share. The firm’s revenue for the quarter was up 34.0% compared to the same quarter last year.
Acorda Therapeutics (ACOR) traded down $0.15 on Friday, reaching $24.40. 238,691 shares of the company’s stock were exchanged, compared to its average volume of 768,002. The company has a current ratio of 3.07, a quick ratio of 2.81 and a debt-to-equity ratio of 0.64. The stock has a market capitalization of $1,175.19, a PE ratio of -5.07 and a beta of 1.64. Acorda Therapeutics has a 52-week low of $13.60 and a 52-week high of $29.75.
In related news, insider David Lawrence sold 31,000 shares of the company’s stock in a transaction that occurred on Friday, January 19th. The shares were sold at an average price of $27.58, for a total transaction of $854,980.00. Following the sale, the insider now directly owns 5,275 shares in the company, valued at approximately $145,484.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 7.90% of the company’s stock.
Several hedge funds have recently made changes to their positions in ACOR. Meadow Creek Investment Management LLC lifted its stake in shares of Acorda Therapeutics by 56.0% during the 4th quarter. Meadow Creek Investment Management LLC now owns 8,736 shares of the biopharmaceutical company’s stock valued at $187,000 after buying an additional 3,136 shares in the last quarter. Crossmark Global Holdings Inc. bought a new stake in Acorda Therapeutics during the 3rd quarter worth approximately $233,000. Teacher Retirement System of Texas bought a new stake in Acorda Therapeutics during the 4th quarter worth approximately $347,000. Municipal Employees Retirement System of Michigan increased its holdings in Acorda Therapeutics by 59.8% during the 3rd quarter. Municipal Employees Retirement System of Michigan now owns 17,510 shares of the biopharmaceutical company’s stock worth $414,000 after acquiring an additional 6,550 shares during the period. Finally, MetLife Investment Advisors LLC bought a new stake in Acorda Therapeutics during the 4th quarter worth approximately $439,000.
WARNING: This piece of content was first posted by Week Herald and is owned by of Week Herald. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://weekherald.com/2018/03/20/125-73-million-in-sales-expected-for-acorda-therapeutics-inc-acor-this-quarter.html.
Acorda Therapeutics Company Profile
Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.